RT Journal Article
SR Electronic
T1 AKI Risk Score (AKI-RiSc): Developing an Interpretable Clinical Score for Early Identification of Acute Kidney Injury for Patients Presenting to the Emergency Department
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.18.21259146
DO 10.1101/2021.06.18.21259146
A1 Yukai Ang
A1 Marcus Eng Hock Ong
A1 Feng Xie
A1 Su Hooi Teo
A1 Lina Choong
A1 Riece Koniman
A1 Bibhas Chakraborty
A1 Andrew Fu Wah Ho
A1 Nan Liu
YR 2021
UL http://medrxiv.org/content/early/2021/06/23/2021.06.18.21259146.abstract
AB Background Acute kidney injury (AKI) in hospitalised patients is a common syndrome associated with poorer patient outcomes. Clinical risk scores can be used for the early identification of patients at risk of AKI.Methods We conducted a retrospective study using electronic health records of Singapore General Hospital emergency department patients who were admitted from 2008 to 2016. The primary outcome was inpatient AKI of any stage within 7 days of admission based on Kidney Disease Improving Global Outcome (KDIGO) 2012 guidelines. AutoScore, a machine learning based algorithm, was used to generate point based clinical scores from the study sample which was divided into training, validation and testing cohorts. Model performance was evaluated using area under the curve (AUC).Results Among the 119,468 admissions, 10,693 (9.0%) developed AKI. 8,491 were stage 1 (79.4%), 906 stage 2 (8.5%) and 1,296 stage 3 (12.1%). The AKI Risk Score (AKI-RiSc) was a summation of the integer scores of 6 variables: serum creatinine, serum bicarbonate, pulse, systolic blood pressure, and diastolic blood pressure. AUC of AKI-RiSc was 0.730 (95% CI: 0.713 – 0.747), outperforming an existing AKI Prediction Score model which achieved AUC of 0.665 (95% CI: 0.646 – 0.679) when evaluated on the same test cohort. At a cut-off of 4 points, AKI-RiSc had a sensitivity of 82.5% and specificity of 46.7%.Conclusion AKI-RiSc is a simple point based clinical score that can be easily implemented on the ground for early identification of AKI in high-risk patients and potentially be applied in healthcare settings internationally.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received funding from Duke-NUS Medical School.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A waiver of consent for EHR data collection was granted, and the study protocol was approved by Singapore Health Services' Centralised Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails of the variables and derived predictive model are available from the corresponding author.